AVITA Medical, Inc. announced it has entered into an exclusive multi-year distribution agreement with Stedical Scientific, Inc. to commercialize PermeaDerm®? Biosynthetic Wound Matrix in the United States. PermeaDerm is cleared by the Food and Drug Administration as a transparent matrix for use in the treatment of a variety of wound types until healing is achieved.

Under the terms of the agreement, AVITA Medical will hold the exclusive rights to market, sell, and distribute PermeaDerm products, including any future enhancements or modifications, within the United States. The initial term is for five years, with the option to renew for an additional five years, contingent upon meeting certain minimum. The Company expects the gross margin from the sale of PermeaDerm to be 50% of the average sales price.

Permea Derm is a biosynthetic matrix that facilitates wound healing while also providing a high level of permeability and biocompatibility. For burn or wound procedures treated with Spray-On Skin?? Cells from the RECELL®?

System, PermeaDerm can be applied to further aid in healing. PermeaDerm are eligible for reimbursement in the U.S. across inpatient and outpatient settings.